Most cited papers from Stedman Clinical Trials

Stedman Clinical Trials

What are the most cited papers from Stedman Clinical Trials?

The most cited paper from Stedman Clinical Trials is "Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline" (Karin Yurko‐Mauro, Deanna McCarthy, Dror Rom et al., 2010), with 575 citations. Next come "A Double‐Blind, Placebo‐Controlled Study With Quetiapine as Adjunct Therapy With Lithium or Divalproex in Bipolar I Patients With Coexisting Alcohol Dependence" (70) and "Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study" (59).

Published FieldAccess

Showing 11 of 11 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline Karin Yurko‐Mauro, Deanna McCarthy, Dror Rom et al. · Alzheimer s & Dementia	May 2010	575
2	A Double‐Blind, Placebo‐Controlled Study With Quetiapine as Adjunct Therapy With Lithium or Divalproex in Bipolar I Patients With Coexisting Alcohol Dependence Mary Stedman, Helen M. Pettinati, E. Sherwood Brown et al. · Alcoholism Clinical and Experimental Research Open access	9 Jul 2010	70
3	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study Jonathan I. Silverberg, Andreas Pinter, Afsáneh Alavi et al. · Journal of the European Academy of Dermatology and Venereology Open access	12 Mar 2021	59
4	Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis Barbara Rewerska, Lawrence Sher, Sady Alpizar et al. · Journal of Allergy and Clinical Immunology Global Open access	22 Nov 2023	47
5	Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial Charles R. Conway et al. · Brain stimulation Open access	18 Dec 2024	43
6	Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report Charles R. Conway et al. · Brain stimulation Open access	Mar 2024	17
7	P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Donald E. Schmechel, Gary Gerard, Nick G. Vatakis et al. · Alzheimer s & Dementia	Jul 2008	13
8	Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study Matthias Augustin et al. · Journal of the European Academy of Dermatology and Venereology Open access	13 Oct 2025	10
9	Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report Charles R Conway et al. · The International Journal of Neuropsychopharmacology Open access	20 Dec 2025	9
10	A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4) Paul T. Scott, Benita Ukkonen, Yoseph Caraco et al. · Med	20 Jun 2025	1
11	Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study Gahan Pandina, Melissa P. DelBello, Stefanie Rassnick et al. · Journal of Affective Disorders Open access	15 Oct 2025	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.